The diagnosis of fatty liver disease requires the integration of various clinical information and examination techniques to differentiate between simple fatty liver and the risk of progression to hepatitis or cirrhosis. Physicians typically start by understanding the patient's dietary habits, alcohol intake, and chronic disease history through a detailed interview, and then combine imaging examinations and liver function indices to establish a preliminary diagnostic direction. In recent years, advancements in non-invasive examinations have significantly improved the accuracy and safety of diagnoses.
The diagnostic process must exclude the possibility of other liver diseases and assess the degree of liver fibrosis. Early detection of fatty liver can delay disease progression through lifestyle adjustments, making regular health check-ups particularly important for high-risk groups. The medical community recommends that individuals with metabolic syndrome, diabetes, or obesity undergo liver-related screenings every two years.
Clinical assessment is the starting point for diagnosis, where physicians systematically collect subjective symptoms and objective data from patients. During the interview, they will inquire in detail about daily alcohol intake (considered high risk if over 20 grams/day for men and over 10 grams/day for women) and assess metabolic symptoms such as diabetes, hyperlipidemia, and obesity. Additionally, a family history of liver disease or metabolic disorders increases the risk of non-alcoholic fatty liver disease.
Physical examination may reveal liver enlargement or tenderness upon palpation, but these clinical signs are not specific indicators. Physicians will observe for symptoms related to cirrhosis, such as jaundice and spider angiomas, and measure body mass index (BMI); a BMI over 24 meets the obesity standard for the population and requires increased attention. Laboratory tests will analyze liver function indices, where abnormal levels of γ-GT and ALT may indicate liver damage, but must be combined with other examinations to exclude viral hepatitis and other causes.
Imaging examinations are key tools for diagnosing fatty liver. Ultrasound is widely used due to its non-invasive nature and low cost, with a typical manifestation known as the "bright liver" phenomenon, where the liver echoes are stronger than those of the kidneys. However, the diagnostic accuracy of ultrasound for fatty liver is about 70-80%, which may be affected by the operator's technique and the patient's body type.
New technologies such as transient elastography (FibroScan) can simultaneously assess the degree of liver fibrosis and fatty liver, becoming a common rapid screening tool in outpatient settings. The examination results must be combined with clinical data; for example, an elevated ALT value accompanied by abnormal elasticity values may indicate progression to non-alcoholic steatohepatitis (NASH).
Non-invasive assessment tools can effectively classify risk groups. Serum index combinations like FibroTest calculate risk scores using seven liver enzymes and inflammation markers, recommending further examination if the score exceeds 0.52. The NAFLD fibrosis score combines age, platelet count, and AST/ALT ratio to categorize patients into high, medium, or low fibrosis risk groups.
Among imaging auxiliary tools, the "Fatty Liver Index" (FLI) from ultrasound is a simple screening tool that combines gender, waist circumference, triglycerides, and ALT values, achieving an accuracy of 75%. For highly suspected cases, physicians may recommend performing MRI-PDFF, which can control measurement error of fat content to within 1.5%.
It is necessary to differentiate from viral hepatitis, metabolic liver diseases, and autoimmune hepatitis. Patients with hepatitis B or C may also have fatty liver, requiring confirmation through viral antibody and viral load tests. Metabolic diseases such as hemochromatosis or Wilson's disease require ferritin and ceruloplasmin measurements.
In autoimmune hepatitis, antinuclear antibodies and immunoglobulin G indices are usually abnormal, while the diagnosis of alcoholic fatty liver requires exclusion of other causes and confirmation based on alcohol consumption and histological characteristics. If ultrasound shows uneven liver density or an irregular surface, further exclusion of liver cancer is necessary.
Early detection of fatty liver can prevent progression to cirrhosis or liver failure. Studies show that patients who control their weight and blood sugar early have a liver fibrosis reversal rate of up to 40%. Screening high-risk groups can be done through simple calculations: a waist circumference of ≥90 cm for men and ≥80 cm for women, along with abnormal triglycerides, can warrant further examination.
Regular follow-up can monitor disease progression, such as measuring ALT values and body fat index every six months. For those who have developed symptoms of portal hypertension, immediate upper gastrointestinal endoscopy is necessary to assess the risk of esophageal varices. Early intervention can reduce the future need for liver transplantation; therefore, the timing and accuracy of diagnosis directly affect prognosis.
The primary goal after diagnosis is to assess the extent of liver damage, typically requiring liver function blood tests, ultrasound, or FibroScan to check for fibrosis. If obesity, diabetes, or hyperlipidemia is present, related metabolic syndrome indicators should also be controlled. Physicians may recommend follow-up liver function and imaging changes in 3-6 months.
Is completely avoiding fats in the diet sufficient to improve fatty liver?Simply eliminating fats is not enough; the key lies in adjusting the types of fats and total caloric intake. It is recommended to reduce trans fats and saturated fats (such as fried foods), increase unsaturated fats (such as salmon and flaxseed), and control refined sugars and refined carbohydrates. Exercise should also be incorporated to reduce intrahepatic fat accumulation.
Are there currently any specific medications for non-alcoholic fatty liver disease (NAFLD)?Currently, there are no approved specific medications, but most patients can improve their condition through lifestyle adjustments. Research in 2023 showed that PPAR agonist drugs demonstrated potential efficacy in clinical trials and may become new therapies in the future. At this stage, treatment still focuses on weight loss, dietary control, and management of metabolic syndrome.
Is it normal for fatty liver patients to experience bloating or pain in the upper right abdomen?Generally, mild fatty liver is asymptomatic; however, if significant pain occurs, it may indicate complications such as hepatitis or worsening fibrosis. Persistent discomfort should prompt immediate medical attention to rule out gallbladder disease or cirrhosis. Regular monitoring of liver status is more reliable than relying solely on symptoms.
Do individuals with normal weight need regular screenings for fatty liver?Yes. Non-alcoholic fatty liver can occur in non-obese populations, especially those with insulin resistance or a family history of liver disease. It is recommended that individuals over 40 years old, those with diabetes, or those with high triglycerides undergo ultrasound screening every two years. Normal weight does not mean there is no risk; metabolic health assessments should be combined.
%201.svg)
Copyright © 2025 MedFrontiers. All Rights Reserved.
